- By Shuda Xia
The largest insider buys this week were for OPKO Health Inc. (OPK), Compass Diversified Holdings (CODI), Acceleron Pharma Inc. (XLRN) and Resolute Energy Corp. (REN).
Opko Health Inc. (OPK): Executive VP-Administration Steven D. Rubin bought 2,000 shares
-
Warning! GuruFocus has detected 3 Warning Signs with OPK. Click here to check it out.
-
The intrinsic value of OPK
Rubin bought 2,000 shares of OPK stock on Dec. 30 at the average price of $9.18 per share. The price of the stock has increased by 2.18% since.
CEO and chairman Phillip Frost bought 20,000 shares of OPK stock on Jan. 3 at the average price of $9.04 per share. The price of the stock has increased by 3.76% since.
Opko Health is an American pharmaceutical and medication company. The company is mainly focused on diagnostics and pharmaceuticals, but also develops treatments for secondary hyperparathyroidism. In 2014, it acquired Laboratorio Arama de Uruguay. The company has a market cap of $5.23 billion, and as of Jan. 6 the company traded at $9.38.
On Jan. 4, Opko Health's shares dropped more than 20% after a human growth hormone product that it had already licensed to Pfizer failed in late-stage clinical trials. The late-stage study included 203 adult patients with growth hormone deficiency. These patients were split into two groups: one group received a placebo and the other received Opko's growth hormone drug. There was no statistically significant difference between the two patient groups.
Compass Diversified Holdings (CODI): Chairman C. Sean Day bought 5,320 shares
Day bought 5,320 shares of CODI stock on Jan. 3 at the average price of $18.16 per share. The price of the stock has decreased by 0.33% since.
Compass Diversified Holdings is an American industrial holdings company whose subsidiaries include Advanced Circuits, American Furniture and Clean Earth. The company has a market cap of $1.08 billion, and as of Jan. 6 it traded at $25.55.
On Jan. 5, Compass Diversifed Holdings announced that its board of directors had declared a quarterly cash distribution of 36 cents per share. The distribution for the quarter ended on Dec. 31, 2016 and is payable on Jan. 26 to all holders of record as of Jan. 19.
Acceleron Pharma Inc. (XLRN): Director Joseph S. Zakrzewski bought 4,000 shares
Zakrzewski bought 4,000 shares of XLRN stock on Dec. 30 at the average price of $25.50 per share. The price of the stock has increased by 2.94% since.
SVP, CFO and Treasurer Kevin Mclaughlin sold 1,700 shares of XLRN stock on Jan. 4 at the average price of $27.45 per share. The price of the stock has decreased by 4.37% since.